Fox Chase Cancer Center

 

Fox Chase Cancer Center
L

SABCS Update on HER2+ MBC: Tucatinib vs. Placebo, T-DXd, Margetuximab + CTX vs. H + CTX, Pyrotinib

By Fox Chase Cancer Center FEATURING Lori Goldstein
By Fox Chase Cancer Center FEATURING Lori Goldstein
33 views
April 13, 2021
0 Comments
Login to view comments. Click here to Login

Featured Video

20:59
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam

Featured Video

21:09
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam
19th Annual Highlights of the 2020 San Antonio Breast Cancer Symposium
06:39
Fox Chase Cancer Center

SABCS Highlights on HR+ HER2- mBC: The All-Oral Regimen of Tesetaxel…

Feat. J. Matro
17:32
Fox Chase Cancer Center

SABCS Takeaways on HR+ eBC: Neoadjuvant Weekly Nab-Paclitaxel vs. Do…

Feat. J. Matro
17:29
Fox Chase Cancer Center

SABCS Update on HER2+ EBC: Extended Adjuvant Neratinib, T-DM1 vs. TH…

Feat. L. Goldstein
13:04
Fox Chase Cancer Center

SABCS Update on HER2+ MBC: Tucatinib vs. Placebo, T-DXd, Margetuxima…

Feat. L. Goldstein
23:31
Fox Chase Cancer Center

Fox Chase SABCS Highlights on Local Control and Ductal Carcinoma In …

Feat. R. Bleicher